Investigational drug · Phase 2
BCMA-CD19-IL-15
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN).
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "BCMA-CD19-IL-15"
First trial start
2026
Apr 7, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BCMA-CD19-IL-15", any sponsor or status.
Conditions studied
As listed on its trial records.
- Inflammatory Bowel Diseases (IBD)
- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BCMA-CD19-IL-15" as an intervention, largest first.
- IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaRecruiting
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT07509086 · 25 participants (planned) · Start Dec 29, 2025 · Primary completion Jul 15, 2028
Drug: IL-15-armored CAR-T cells · For: Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL)
Sites: Changchun, China
iCell Gene TherapeuticsIndustry
NCT07328581 · 20 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion · For: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN)
Sites: Chicago, Illinois; Hawthorne, New York; New Hyde Park, New York · 4 sites in all
iCell Gene TherapeuticsIndustry
NCT07544160 · 18 participants (planned) · Start Apr 7, 2026 · Primary completion Apr 7, 2028
Drug: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T · For: Inflammatory Bowel Diseases (IBD)
Sites: Zhongshan, China
iCell Gene TherapeuticsIndustry
NCT07715136 · 10 participants (planned) · Start Mar 20, 2025 · Primary completion Dec 31, 2027
Drug: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T · For: Inflammatory Myopathy
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Inflammatory Bowel Diseases (IBD)
- ICG318Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.